M BCR ABL
Philadelphia Chromosome; major t(9;22) e13/e14(p210), minor t(9;22) e1 (p190)
Chronic myelogenous leukemia (CML), Acute lymphoblastic leukemia (ALL), Allogeneic bone marrow transplantation, Minimal residual disease (MRD), Molecular remission;
Tyrosine Kinase Inhibitors
Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) for BCR/ABL major t(9;22) e13/e14(p210) and minor t(9;22) e1 (p190) fusion gene transcipts.
10.0 mL (min. 9.0 mL) peripheral blood in EDTA
5.0 mL (min. 2.5 mL) bone marrow in EDTA
Ship peripheral blood and bone marrow at ambient temperature (Do not ship on ice or cold pack)
Please notify us if shipment is to arrive after 1 p.m. Friday or Saturday
Specimen >48 hours old; Specimen clotted; Specimen stored or shipped at incorrect temperature; Specimen in incorrect anticoagulant; Insufficient specimen volume
Positive: major or minor BCR/ABL fusion quantified relative to ABL
Negative: major or minor BCR/ABL fusion not detected, less than 0.001% BCR/ABL
Molecular detection of the BCR/ABL fusion gene transcript (e13a2, e14a2, e1a2) in patients with a Philadelphia (t[(9;22)(q34;q11.2)]) positive leukemia. The translocation is found in >99% of CML patients, ~20% of adult acute lymphoblastic leukemia (ALL), ~5% of pediatric ALL, and ~2% of acute myeloid leukemia (AML).
The primary clinical utilities for BCR/ABL quantitative PCR testing include (1) identfication of fusion gene transcript and determination of baseline level of BCR-ABL expression in newly diagnosed CML patients, and (2) the monitoring of patients for molecular evidence of minimal residual disease (MRD) or molecular remission in response to tyrosine kinase inhibitor (TKI) therapy or allogeneic stem cell transplantation.
Gleevec® is a registered trademark of the Novartis Pharmaceuticals Corporation.